Ignite Creation Date:
2025-12-25 @ 4:58 AM
Ignite Modification Date:
2025-12-26 @ 3:58 AM
Study NCT ID:
NCT04889118
Status:
COMPLETED
Last Update Posted:
2025-12-23
First Post:
2021-05-12
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-07-14
Start Date Type:
ACTUAL
Primary Completion Date:
2023-01-18
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-11-01
Completion Date Type:
ACTUAL
First Submit Date:
2021-05-12
First Submit QC Date:
None
Study First Post Date:
2021-05-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-01-05
Results First Submit QC Date:
None
Results First Post Date:
2024-07-09
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-04
Last Update Post Date:
2025-12-23
Last Update Post Date Type:
ESTIMATED